Книга Что скрывают противозачаточные. Как вернуть контроль над своими гормонами за 30 дней, страница 101. Автор книги Джолин Брайтен

Разделитель для чтения книг в онлайн библиотеке

Онлайн книга «Что скрывают противозачаточные. Как вернуть контроль над своими гормонами за 30 дней»

Cтраница 101

Orio, F., et al. “Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome”. Minerva Ginecologica 60, no. 1 (2008): 39–51.

Pelusi, B., et al. “Type 2 Diabetes and the Polycystic Ovary Syndrome”. Minerva Ginecologica 56, no. 1 (2004): 41–51.

Pomp, E. R., et al. “Risk of Venous Thrombosis: Obesity and Its Joint Effect with Oral Contraceptive Use and Prothrombotic Mutations”. British Journal of Haematology 139, no. 2 (2007): 289–96.

Raghuramulu, N., et al. “Vitamin D Improves Oral Glucose Tolerance and Insulin Secretion in Human Diabetes”. Journal of Clinical Biochemistry and Nutrition 13, no. 1 (1992): 45–51.

Raitakari, M., et al. “Distribution and Determinants of Serum High-Sensitive C-Reactive Protein in a Population of Young Adults: The Cardiovascular Risk in Young Finns Study”. Journal of Internal Medicine 258, no. 5 (2005): 428–34.

Roach, R. E., et al. “Combined Oral Contraceptives: The Risk of Heart Attack and Stroke in Women Using Birth Control Pills”. Cochrane Database of Systematic Reviews no. 8 (2015): CD011054. Roberfroid, M., et al. “Prebiotic Effects: Metabolic and Health Benefits”. British Journal of Nutrition 104, suppl. 2 (2010): S1–63.

Rocha, S. L., et al. “Heart Attack in a Young Woman – All About Genetics!” Journal of US- China Medical Science 14 (2017): 28–30.

https://www.davidpublisher.com/Public /uploads/Contribute/58b7979d5aba9.pdf.

Rosing, J., et al. “Low-Dose Oral Contraceptives and Acquired Resistance to Activated Protein C: A Randomised Cross-over Study”. Lancet 354, no. 9195 (1999): 2036–40.

Rosing, J., et al. “Oral Contraceptives and Venous Thrombosis: Different Sensitivities to Activated Protein C in Women Using Second- and Third-Generation Oral Contraceptives”. British Journal of Haematology 97, no. 1 (1997): 233–38. Samsioe, G. “Coagulation and Anticoagulation Effects of Contraceptive Steroids”. American Journal of Obstetrics and Gynecology 170, no. 5, pt. 2 (1994): 1523–27.

Samsunnahar, Q. S. A., et al. “Assessment of Coagulation Disorder in Women Taking Oral Contraceptives”. Journal of Bangladesh Society of Physiologist 9, no. 1 (2014): 1–5.

Sasieni, P. “Cervical Cancer Prevention and Hormonal Contraception”. Lancet 370, no. 9599 (2007): 1591–92.

Seeger, J. D., et al. “Risk of Thromboembolism in Women Taking Ethinylestradiol/ Drospirenone and Other Oral Contraceptives”. Obstetrics and Gynecology 110, no. 3 (2007): 587–93.

Shoelson, S. E., et al. “Inflammation and Insulin Resistance”. Journal of Clinical Investigation 116, no. 7 (2006): 1793–1801.

Sidney, S., et al. “Venous Thromboembolic Disease in Users of Low-Estrogen Combined Estrogen-Progestin Oral Contraceptives”. Contraception 70, no. 1 (2004): 3–10.

Singh, B., et al. “Resveratrol Inhibits Estrogen-Induces Breast Carcinogenesis Trough Induction of NRF2-Mediated Protective Pathways”. Carcinogenesis 35, no. 8 (2014): 1872–80.

Skouby, S. O., et al. “Contraception for Women with Diabetes: An Update”. Bailliére’s Clinical Obstetrics and Gynaecology 5, no. 2 (1991): 493–503.

Smith J. S., et al. “Cervical Cancer and Use of Hormonal Contraceptives: A Systematic Review”. Lancet 361, no. 9364 (2003): 1159–67.

Soares, G. M., et al. “Metabolic and Cardiovascular Impact of Oral Contraceptives in Poly cystic Ovary Syndrome”. International Journal of Clinical Practice 63, no. 1 (2009): 160–69.

Sørensen, C. J., et al. “Combined Oral Contraception and Obesity Are Strong Predictors of Low-Grade Inflammation in Healthy Individuals: Results from the Danish Blood Donor Study (DBDS)”. PLoS One 9, no. 2 (2014): e88196.

Tayyebi-Khosroshahi, H., et al. “Effect of Treatment with Omega-3 Fatty Acids on C-Reactive Protein and Tumor Necrosis Factor-Alfa in Hemodialysis Patients”. Saudi Journal of Kidney Diseases and Transplantation 23, no. 3 (2012): 500–6.

Tys-Jacobs, S., et al. “Vitamin D and Calcium Dysregulation in the Polycystic Ovarian Syndrome”. Steroids 64, no. 6 (1999): 430–35.

Vandenbroucke, J. P., et al. “Increased Risk of Venous Thrombosis in Oral-Contraceptive Users Who Are Carriers of Factor V Leiden Mutation”. Lancet 344, no. 8935 (1994): 1453–57.

Van Hylckama, V. A., et al. “The Venous Thrombotic Risk of Oral Contraceptives, Effects of Oestrogen Dose and Progestogen Type: Results of the MEGA Case-Control Study”. British Medical Journal 339 (2009): b2921. Vasilakis, C., et al. “Risk of Idiopathic Venous Thromboembolism in Users of Progestagens Alone”. Lancet 354, no. 9190 (1999): 1610–11.

Vasilakis, C., et al. “The Risk of Venous Thromboembolism in Users of Postcoital Contraceptive Pills”. Contraception 52, no. 2 (1999): 79–83.

Vessey, M., et al. “Oral Contraceptive Use and Cancer. Findings in a Large Cohort Study 1968–2004”. British Journal of Cancer 95, no. 3 (2006): 385–89.

Vinogradova, Y., et al. “Use of Combined Oral Contraceptives and Risk of Venous Tromboembolism: Nested Case-Control Studies Using the QResearch and CPRD Databases”. British Medical Journal 350 (2015): h2135.

Wang, Q., et al. “Effects of Hormonal Contraception on Systemic Metabolism: Cross- Sectional and Longitudinal Evidence”. International Journal of Epidemiology 45, no. 5 (2016): 1445–57.

Westhof, C. L., et al. “Clotting Factor Changes During the First Cycle of Oral Contraceptive Use”. Contraception 93, no. 1 (2016): 70–76.

Williams, M. J., et al. “Association Between C-Reactive Protein, Metabolic Cardiovascular Risk Factors, Obesity, and Oral Contraceptive Use in Young Adults”. International Journal of Obesity and Related Metabolic Disorders 28, no. 8 (2004): 998–1003.

Yan, Y., et al. “Omega-3 Fatty Acids Prevent Inflammation and Metabolic Disorder Trough Inhibition of NLRP3 Infammasome Activation”. Immunity 38, no. 6 (2013): 1154–63.

9. Возьмите под контроль свои перепады настроения, тревожное расстройство и депрессию

Akhondzadeh, S., et al. “Passionfower in the Treatment of Generalized Anxiety: A Pilot Double-Blind Randomized Controlled Trial with Oxazepam”. Journal of Clinical Pharmacy and Therapeutics 26, no. 5 (2001): 363–67.

Almey, A., et al. “Estrogen Receptors in the Central Nervous System and Their Implication for Dopamine-Dependent Cognition in Females”. Hormones and Behavior 74 (2015): 125–38.

Anxiety and Depression Association of America. “Facts & Statistics”. https://adaa.org/about-adaa/press-room/facts-statistics#.

Arbo, B. D., et al. “Effect of Low Doses of Progesterone in the Expression of the GABA(A) Receptor α4 Subunit and Procaspase-3 in the Hypothalamus of Female Rats”. Endocrine 46, no. 3 (2014): 561–67.

Arevalo, M. A., et al. “Selective Oestrogen Receptor Modulators Decrease the Inflammatory Response of Glial Cells”. Journal of Neuroendocrinology 24, no. 1 (2012): 183–90.

Вход
Поиск по сайту
Ищем:
Календарь
Навигация